PFO
CVAC

Pathstone Family Office’s CureVac CVAC Stock Holding History

Pathstone Family Office’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$89.1K Buy
+13,042
New +$115K ﹤0.01% 1596

Other funds holding CVAC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Pathstone Family Office's CVAC Position: Q3 2023 in Review

Pathstone Family Office opened a new position in CureVac (CVAC) in Q3 2023: 13,042 shares worth $89.1K. The stake represents ﹤0.01% of the portfolio and ranks #1596 among its holdings.

84 funds tracked by Wall St. Rank hold CVAC as of Q3 2023.

  • Pathstone Family Office held 13,042 shares of CureVac worth $89.1K as of Q3 2023.
  • CureVac was a new Pathstone Family Office position in Q3 2023.
  • CureVac made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1596 holding.
  • 84 funds tracked by Wall St. Rank held CureVac as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.